Navigation Links
ProActive Remedies, LLC Announces Launch of New Allergy Medication
Date:3/27/2008

WINDSOR, Colo., March 27 /PRNewswire/ -- A new patent-pending allergy medication and treatment method is available over the counter as an alternative to allergy shots. ProActive Remedies, LLC announced today that it has begun selling ALLERTHERAPY for the treatment of allergies. The oral immunotherapy spray helps allergy sufferers by building immunity to a wide variety of targeted allergens through the administration of low homeopathic concentrations of such allergens. Over time, this treatment may save money for allergy sufferers through decreased doctor visits, absences, medications, and complications by reducing allergic reactions. ProActive Remedies, LLC sells directly to allergy sufferers through its online store at http://www.allertherapy.com.

To date, ProActive Remedies, LLC has brought to market the ALLERTHERAPY Pollen Mix medication, and anticipates releasing food, environment, and combination mixes this spring. ProActive Remedies, LLC's ALLERTHERAPY line offers an assortment of features including multi-regional, multi-seasonal formulas, a wide variety of targeted allergens, reduced dependence upon allergy medications -- including ALLERTHERAPY itself -- over time, and a 30 Day Unconditional Guarantee. Treatment can reduce the severity of allergic reactions by fifty percent or more. This translates into substantial future savings. Additional benefits to allergy sufferers are the improvements in lifestyle that come with increased allergen tolerance. Improved indoor and outdoor comfort, improved tolerance of pets, and the ability to widen the variety of foods in the food allergy sufferer's diet are among the advantageous results of the ALLERTHERAPY Treatment Method.

According to American Academy of Allergy Asthma & Immunology (AAAAI) estimates, more than twenty percent of Americans are affected by allergic diseases. These allergic diseases are the sixth leading cause of chronic disease
'/>"/>

SOURCE ProActive Remedies, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Virginia School District Gets Proactive Against MRSA
2. Cancer care providers need to proactively address patients psychological and social needs
3. BJs Charitable Foundation Announces Q4 Donation of More Than $500,000 to Programs That Benefit Children and Families
4. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
5. ThalesNano Announces the Launch of X-Cube Flash(TM), its Next Generation High Temperature and Pressure Continuous Process Reactor
6. Laureate Announces Second Manufacturing Agreement with Cytheris
7. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
8. Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A Clean Slate Approach to the Practice of Pharmaceutical Care
9. FEW Announces Legislative Goals for Remainder of 110th Congress; Delivers Fact Sheets to Legislators
10. Hillenbrand Industries, Inc. Announces Pricing of Its Pending Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
11. EnergyNow! Announces New Grant Funding to Combat Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...MMR shots found itself in the eye of a storm in th... to autism in some cases.// Recent statistics enab...firmed their faith in the MMR shots, and are well ... from Measles, Mumps and Rubella. The number of M...
...Researchers at the George Institute for Internatio...hat heart disease is the number one killer in rura...a large survey in Andhra Pradesh. The findings of ...rnal of Epidemiology this week. The report said In...
...New study by prescription manager Medco Health sol...ke ADHD medicine end up taking the drugs themselve...000 children and their parents last year. The stu...g ADHD medicine, it is more likely that the other ...
...Tonsillitis, a throat disease common among kids, c...apy, says a new study. // Children aged three-sev...lly caused by viruses, though certain bacteria are...illitis. Michael Pichichero and colleagues at the...
Other Medicine News:Health News:Chronic Diseases Rampant In Rural India 2
(Date:8/18/2008)... JERUSALEM, Israel, August 18 /PRNewswire-FirstCal...) ( http://www.oramed.com ), a developer,of oral d..., entitled "Open,Label Study to Assess the Safety,...f Five Oral Insulin Formulations in Healthy,Subjec...ing 44th Annual,Meeting of the European Associatio...
(Date:8/18/2008)...Industry Leader with Strong Clinical Research Rela...owth Organizations to Lead Commercialization, SAN...- NewCardio, Inc.,(OTC Bulletin Board: NWCI) a ca...nced that Vincent W. Renz has joined NewCardio as ... commercialization effort, to include,business dev...
(Date:8/18/2008)... BETHESDA, Md., Aug. 18 /- ...al company developing novel, proprietary,antibodie...toimmune,diseases, will host a webcast and confere... 10:00 a.m. Eastern Time (4:00 p.m. Central Europe...e published in the Journal,SCIENCE on August 15, 2...
(Date:8/15/2008)... AUDUBON, Pa., Aug. 15 /- Globus Medi...nt manufacturer in the world, today announced,that...en implanted under an,Investigational Device Exemp...ald Johnson II and Dr. Rhett Murray., The FLEXUS(...tween two,spinous processes with minimal disruptio...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 1Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2291 4Drinking polyphenol rich Concord grape juice may improve memory in older adults 20857 1Drinking polyphenol rich Concord grape juice may improve memory in older adults 20857 2Louisiana May Mandate Fluoridation Despite Evidence of Harm 20853 1Louisiana May Mandate Fluoridation Despite Evidence of Harm 20853 2Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 1Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 2Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 3Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY 28TM 29 Wound 26 Burn Dressings at Upcoming WUWHS Conference 20849 4
..., Calif., May 02, 2007 /PRNewswire/ -- Ceregene, I...hase 1 trial of,CERE-110, a gene therapy product d...he treatment of Alzheimer,s disease. After one,yea...ho received,CERE-110 in the trial indicate that a ...rated, and an interim analysis suggested that,the ...
...Y, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data ha...sclerosis (RRMS),patients treated with COPAXONE(R)...munosuppression with mitoxantrone experienced a,90...MRI)-monitored,disease activity compared to their ...d were sustained throughout the 24-month study,per...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: